Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01296087 · ClinicalTrials.gov registry record · Phase 2

TC-6987 for the Treatment of Mild to Moderate Asthma

A Phase 2 study of Asthma, sponsored by Targacept.

Completed
Registry status
Phase 2
Development phase
203
Enrollment target
20
Study locations

NCT01296087: Completed Phase 2 study of Asthma, sponsored by Targacept.

NCT01296087 is a Phase 2 study of Asthma that has completed, run by Targacept. The registered enrollment target is 203 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01296087, a Phase 2 study of Asthma, has completed, sponsored by Targacept.

COMPLETED
Registry status
Phase 2
Development phase
203 participants
Enrollment target
20
Study locations

Study Summary

This study is designed to determine whether TC-6987 improves respiratory function in subjects with asthma by reducing airway hyper-responsiveness and inflammation.

Primary Outcome

Co-primary efficacy endpoints: 1. the change in FEV1 from pre dose on Day 1 to pre dose on Day 28 2. the change in FEV1 from pre dose on Day 1 to 2 h post dose on Day 28

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG TC-6987

Study Locations (20)

Florida

  • Avail Clinical Research LLC - DeLand
  • Sarasota Clinical Research - Sarasota
  • Florida Pulmonary Research Institute, Inc. - Winter Park

California

  • California Allergy and Asthma Medical Group, Inc. - Los Angeles
  • California Allergy & Asthma Medical Group - Palmdale

Pennsylvania

  • Altoona Lung Specialists - Altoona
  • Allergy & Asthma Research of New Jersey, Inc. - Philadelphia

Texas

  • Pioneer Research Solutions - Houston
  • Paragon Research - San Antonio

Alabama

  • Clinical research Center of Alabama - Birmingham

Arizona

  • Medical Research of Arizona - Scottsdale

Connecticut

  • Waterbury Pulmonary Associates - Waterbury

North Carolina

  • Allergy Partners of Western North Carolina - Asheville

Trial Details

FieldValue
Enrollment Target 203 participants
Start Date 2011-02
Est. Completion 2012-01
Phase Phase 2
Targacept

13 total trials

What the finished NCT01296087 record still lists

NCT01296087 is an interventional study that assigns participants to a tested intervention. The registered 203 participants enrollment target is mid-sized for trials with a published cap, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (87% lower).

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01296087 names 20 study sites across 15 states, led by Florida, California, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT01296087 about?

NCT01296087 is a clinical study titled "TC-6987 for the Treatment of Mild to Moderate Asthma". This study is designed to determine whether TC-6987 improves respiratory function in subjects with asthma by reducing airway hyper-responsiveness and inflammation.

What is the current status of trial NCT01296087?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 203 participants. The study started on 2011-02. Estimated completion is 2012-01.

What conditions does trial NCT01296087 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT01296087?

The interventions under investigation include: Placebo (DRUG), TC-6987 (DRUG).

Who is sponsoring clinical trial NCT01296087?

This trial is sponsored by Targacept, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01296087 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01296087's enrollment target sits among peer trials

203 159th of 374 higher than 215 of 374 other Asthma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05652686 · 203 participants · Phase 1

    A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

  • NCT06063122 · 203 participants · NA

    Development of a Therapeutic Device to Improve Speech Sound Differentiation in Preterm Infants

  • NCT07031245 · 203 participants · NA

    Evidence-Based Quality Improvement to Reduce VA Primary Care Burnout

  • NCT03481010 · 204 participants · NA

    Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01296087, the US trial registry maintained by the National Library of Medicine. NCT01296087 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.